HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Acebutolol (Prent)

A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.

Also Known As:

Prent; Sectral; Acebutolol Heumann; Acebutolol Hydrochloride; Acetobutolol; Acébutolol-ratiopharm; Apo-Acebutolol; Apotex Brand of Acebutolol Hydrochloride; Bayer Brand of Acebutolol Hydrochloride; Gepepharm Brand of Acebutolol; Heumann Brand of Acebutolol Hydrochloride; Italfarmaco Brand of Acebutolol Hydrochloride; Lafon-Ratiopharm Brand of Acebutolol Hydrochloride; M & B 17803A; M&B-17803 A; Monitan; Neptal; Novo-Acebutolol; Novopharm Brand of Acebutolol Hydrochloride; Proctor & Gamble Brand of Acebutolol Hydrochloride; Rhodiapharm Brand of Acebutolol Hydrochloride; Rhotral; Rhône-Poulenc Rorer Brand of Acebutolol Hydrochloride; Specia Brand of Acebutolol Hydrochloride; Wyeth Brand of Acebutolol Hydrochloride; Acebutolol Gepepharm Brand; Acébutolol ratiopharm; Acébutololratiopharm; Apo Acebutolol; ApoAcebutolol; Heumann, Acebutolol; Hydrochloride, Acebutolol; Lafon Ratiopharm Brand of Acebutolol Hydrochloride; M&B 17803 A; M&B17803 A; Novo Acebutolol; NovoAcebutolol; Rhône Poulenc Rorer Brand of Acebutolol Hydrochloride; Butanamide, N-(3-acetyl-4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-, (+-)-

Networked: 316 relevant articles (46 outcomes, 55 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Choi, Jun Shik: 2 articles (06/2003 - 08/2002)
2.	Pieniazek, W: 2 articles (01/2001 - 01/2001)
3.	Taylor, Frederick R: 1 article (09/2013)
4.	Ramakrishnan, Rema: 1 article (09/2013)
5.	Kane, Robert L: 1 article (09/2013)
6.	Shamliyan, Tatyana A: 1 article (09/2013)
7.	Miller, Jennifer Biggs: 1 article (09/2013)
8.	Wang, Shi-Yi: 1 article (09/2013)
9.	Choi, Jae-Young: 1 article (09/2013)
10.	Tyczka, Joanna: 1 article (06/2013)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/1985 - "Beta-blockade by acebutolol was highly effective in treating mild-moderate arterial hypertension in the elderly." 10/01/1981 - "In mild hypertension good results increased from 75% after acebutolol only to 100% after this combination. " 10/06/1983 - "It can therefore be concluded that acebutolol is a beta-adrenolytic drug which is reliably effective in the treatment of essential arterial hypertension, well tolerated and easily administered." 01/01/1983 - "The results of this pilot study suggest that acebutolol warrants further investigation as an effective and well-tolerated treatment of hypertension in pregnancy." 01/01/2002 - "With regard to the results of our clinical study we can consider acebutolol to be effective and safe antihypertensive drug in the treatment of hypertension in pregnancy."
2.	Cardiac Arrhythmias (Arrythmia) 05/01/1985 - "The antiarrhythmic activity of acebutolol, its ancillary pharmacologic properties, and its tolerance by a diverse group of patients make acebutolol a significant tool for the clinician in the management of chronic arrhythmia." 01/01/1975 - "It was concluded that acebutolol is a cardioselective beta-blocker which by intravenous route may be useful in the treatment of selected cardiac arrhythmias." 11/01/1984 - "[Efficacy of acebutolol in hypertensive and arrhythmia patients]." 04/01/1991 - "Chronic use of acebutolol in the treatment of cardiac arrhythmias." 02/01/1983 - "Suppression of ventricular arrhythmia by acebutolol."
3.	Myocardial Infarction 03/01/1997 - "The APSI trial was a randomized placebo-controlled trial designed to assess the efficacy of 1 year of treatment by acebutolol in high-risk patients who had survived an acute myocardial infarction. " 09/25/1990 - "Efficacy of acebutolol after acute myocardial infarction (the APSI trial). " 09/25/1990 - "A randomized, placebo-controlled trial was carried out to determine the effectiveness of acebutolol in preventing late death in high-risk patients surviving an acute myocardial infarction (MI). " 08/01/1990 - "Acebutolol et Prévention Secondaire de l'Infarctus (APSI), a randomized, placebo-controlled trial, was designed to test long-term acebutolol, 200 mg twice daily, a beta blocker with mild intrinsic sympathomimetic activity, in the prevention of late death in high-risk postacute myocardial infarction (AMI) patients. " 09/01/1985 - "The hemodynamic dose-response effects of intravenous (25 and 50 mg) and oral (200 and 400 mg) acebutolol were compared in a randomized between-group study in men within 17 hours of an acute uncomplicated myocardial infarction. "
4.	Ventricular Premature Complexes (Premature Ventricular Contraction) 03/01/1986 - "Oral acebutolol is also effective in suppressing premature ventricular contractions, and in small numbers of patients generally beneficial results were obtained in supraventricular and ventricular arrhythmias with intravenous administration. " 05/01/1985 - "The safety and efficacy of oral acebutolol therapy for the suppression of premature ventricular contractions (PVCs) were assessed in two clinical trials pooled for analysis. " 05/01/1985 - "Acebutolol for premature ventricular contractions: short- and long-term effects." 01/01/1984 - "[Intravenous acebutolol in supraventricular arrhythmias and ventricular extrasystole. " 05/01/1983 - "Reduction of ventricular ectopic beats with oral acebutolol: a double-blind, randomized crossover study."
5.	Coronary Artery Disease (Coronary Atherosclerosis) 09/01/1987 - "Systemic and coronary hemodynamic effects of acebutolol (10 mg i.v.), a cardioselective beta-adrenoceptor blocking agent were investigated in 11 patients with coronary artery disease and significant arterial obstructive lesions. " 05/01/1985 - "In 11 patients (10 men, one woman) with coronary artery disease, acebutolol at 1 mg/kg infused over 15 minutes decreased heart rate and slowed conduction, increased the refractoriness of the atrioventricular node without a significant change in the atrial refractoriness, and at plasma levels greater than or equal to 1000 ng/ml slowed His-Purkinje conduction. " 07/01/1984 - "The hemodynamic dose-response effects of intravenous acebutolol, a cardioselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity, were evaluated in 12 male subjects with angiographically confirmed coronary artery disease. " 07/01/1982 - "Acebutolol, a relatively cardioselective beta-adrenergic blocking drug, was administered to 20 men with coronary artery disease and angina. " 07/01/1982 - "Favorable effects of acebutolol on exercise performance and angina in men with coronary artery disease."

Related Drugs and Biologics

1.	Nifedipine (Adalat)
2.	Propranolol (Inderal)
3.	Hydrochlorothiazide (Esidrix)
4.	Atenolol (Tenormin)
5.	Pindolol (LB 46)
6.	Calcium Channels (Calcium Channel)
7.	Oxprenolol (Trasicor)
8.	Alprenolol
9.	Prazosin (Minipress)
10.	Diuretics

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration
3.	Intravenous Infusions
4.	Aftercare (After-Treatment)
5.	Withholding Treatment